Drawing for RX ALTONA

USPTO serial 86905390

RX ALTONA

Reviewed by CopyMark Law Group

Status 605
Filing date
Status date
Registration date
—
Examiner
KUNG, KAELIE ELIZABETH
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with RX ALTONA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Douglas N. Masters

DOUGLAS N. MASTERS LOEB & LOEB LLP321 N. CLARK STREET, SUITE 2300CHICAGO, IL 60654UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemicals used in industry and science; chemical preparations for use in photography; chemicals used in agriculture, horticulture and forestry except fungicides, herbicides, insecticides and parasiticides; chemical reagents for non-medical purposes; enzymes and proteins for scientific and research purposes; diagnostic preparations for scientific purposes; kits comprised primarily of diagnostic preparations for analysis of food products and water for scientific and research use; diagnostic preparations and reagents for clinical use; diagnostic scanning reagents for scientific use; diagnostic preparations for medical laboratory testingABANDONED—
005Pharmaceutical, veterinary preparations and substances for the treatment of cancer, immune and autoimmune diseases, cardiac diseases, metabolic and endocrine disorders, blood disorders including coagulation, transmissible agents, therapeutic drug monitoring and identification of drugs of abuse; sanitary preparations for medical use; antitoxic sera and pharmaceutical preparations in the nature of antisera for the treatment of cancer, immune and autoimmune diseases, cardiac diseases, metabolic and endocrine disorders, blood disorders including coagulation, transmissible agents, therapeutic drug monitoring and identification of drugs of abuse; diagnostic preparations for medical purposes; kits comprised of diagnostic preparations for medical purposes; diagnostic scanning agents for medical purposes; clinical diagnostic preparations for medial and veterinary use; diagnostic testing preparations for medical and veterinary use; reagents for use in diagnostic tests for medical and veterinary purposes; reagents for use with analyzers for medical and veterinary purposesABANDONED—
009Computer software, none for use in connection with radiation treatment, for use in conjunction with diagnostic testing apparatus, namely, software to control sample handling, sample processing, sample result reporting and test apparatus system robotics; diagnostic apparatus and instruments, not for medical purposes, namely, diagnostic apparatus for the detection of pathogens for laboratory or research use and apparatus for immunoassay procedures, namely, the measurement of antibodies, immunoglobulins, hormones and drugs; diagnostic testing apparatus and instruments for the testing of clinical chemistry for use in immunoassay procedures, not for medical purposes; diagnostic imaging apparatus for use in immunoassay procedures and the study of chemical compounds and structures other than for medical use; clinical laboratory analytical instruments other than for medical use, namely, clinical chemistry or immunoassay analyzersABANDONED—
010Medical apparatus and instruments for use in biomarker diagnostics; diagnostic apparatus and instruments for medical use, namely, biomarkers for detecting and analyzing infectious and non-infectious diseases, organ function in humans and animals, therapeutic drugs and drugs of abuse, proteins, acids and antioxidants; electromagnetic diagnostic imaging apparatus for medical use; clinical chemistry analyzers for use in analyzing biological samples for medical and veterinary use; diagnostic testing apparatus and instruments for detection of proteins use in immunoassay procedures; haematology analyzers for medical diagnostic use; clinical laboratory analytical instruments for medical and veterinary use, namely, apparatus for clinical diagnosis in the field of biomarkersABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 11, 2018MAB5ABANDONMENT NOTICE MAILED - AFTER PUBLICATION—
Apr 11, 2018ABN5ABANDONMENT - AFTER PUBLICATION—
Apr 10, 2018EXARTEAS EXPRESS ABANDONMENT RECEIVED—
Mar 29, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 27, 2018EX2GSOU EXTENSION 2 GRANTED—
Mar 27, 2018EXT2SOU EXTENSION 2 FILED—
Mar 27, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 8, 2017EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 6, 2017EX1GSOU EXTENSION 1 GRANTED—
Sep 6, 2017EXT1SOU EXTENSION 1 FILED—
Sep 6, 2017EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 28, 2017NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jan 31, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 31, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 11, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 29, 2016PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Dec 22, 2016CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 22, 2016XAECEXAMINER'S AMENDMENT ENTERED—
Dec 22, 2016GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Dec 22, 2016GNEAEXAMINERS AMENDMENT E-MAILED—
Dec 22, 2016CNEAEXAMINERS AMENDMENT -WRITTEN—
Dec 16, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 16, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 14, 2016ALIEASSIGNED TO LIE—
Nov 30, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 4, 2016DOCKASSIGNED TO EXAMINER—
May 31, 2016GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 31, 2016GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 31, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 26, 2016DOCKASSIGNED TO EXAMINER—
Feb 18, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 15, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance